Document is current
Any future updates will be listed below
-
Authors
Parrondo, Ricardo D. http://orcid.org/0000-0002-9314-9933
LaPlant, Betsy R.
Elliott, Jamie
Fernandez, Andre
Flott, Caitlin J.
Arrington, Diedre
Chapin, Dustin
Brown, Jade
Das, Saurav http://orcid.org/0000-0003-0597-8123
Roy, Vivek http://orcid.org/0000-0002-5950-4620
Chanan-Khan, Asher A.
Ailawadhi, Sikander http://orcid.org/0000-0002-8377-8111
-
Funding
Funding for this research was provided by:
Mayo Clinic Cancer Center, Department of Hematology Oncology
- License Information
-
More Information
Article History
Received: 22 June 2024
Revised: 13 August 2024
Accepted: 28 August 2024
First Online: 5 September 2024
Competing interests
: BRL, JE, AF, CJF, DA, DC, JB, SD and VR have no conflicts of interest to declare. RDP serves on the advisory board for Sanofi Aventis and Astra Zeneca and has received research funding from Bristol Myers Squibb Foundation and GlaxoSmithKline. SA has provided consultancy for Celgene, Amgen, Janssen and Takeda, and has received research funding from Pharmacyclics, Cellectar and Janssen. AAC-K has received research funding from Xencor Pharmacyclics, Merck, Janssen, Ascentage and Millennium.
: The study protocol and all amendments were reviewed and approved by the Institutional Review Board at Mayo Clinic Florida (IRB # 18-003574). The study was conducted in accordance with the International Conference on Harmonisation Good Clinical Practice guidelines, the principles originating from the Declaration of Helsinki, and study site-specific regulations. All patients provided written informed consent.
